SCD, stearoyl-CoA desaturase, 6319

N. diseases: 225; N. variants: 4
Disease: Malignant neoplasm of liver ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0345904
Disease: Malignant neoplasm of liver
Malignant neoplasm of liver 		0.320 Biomarker disease BEFREE To our knowledge, this is the first evidence that sorafenib disrupts lipogenesis and triggers liver cancer cell death by targeting SCD1 through the ATP-AMPK-mTOR-SREBP1 pathway.-Liu, G., Kuang, S., Cao, R., Wang, J., Peng, Q., Sun, C. Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids <i>via</i> the ATP-AMPK-mTOR- SREBP1 signaling pathway. 31199678 2019
CUI: C0345904
Disease: Malignant neoplasm of liver
Malignant neoplasm of liver 		0.320 Biomarker disease BEFREE Targeting SCD1 in combination with sorafenib may be a novel therapeutic strategy against liver cancer. 28647567 2017
CUI: C0345904
Disease: Malignant neoplasm of liver
Malignant neoplasm of liver 		0.320 Biomarker disease CTD_human Stearoyl-CoA desaturase 1 (Scd1) gene overexpression is associated with genetic predisposition to hepatocarcinogenesis in mice and rats. 12419843 2002